Effect of Anti-diabetic Drugs on Glycemic Variability

Sponsor
Centro de Diabetes Curitiba Ltda
Study ID
NCT02925559
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
  • Gliclazide MR — DRUG
    As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.

Study Details

Objectives Primary objective: To access the change from baseline to week 12 in MAGE index of glycemic variability measured by CGMS for dapagliflozin versus. gliclazide MR. Secondary objectives: 1. Change from baseline to week 12 in glycated hemoglobin A1c (HbA1c), fasting plasma glucose, postprandial glucose and achievement of HbA1c ≤6.5% and \<7% at the end of the study) for dapagliflozin versus gliclazide MR. 2. Change from baseline to week 12 in glycemic variability defined by the interquartile range (IQR - interval between 25th and 75th percentiles) measured by CGMS for dapagliflozin versus gliclazide MR. 3. Change from baseline to week 12 in glycemic variability measured by the Standard Deviation of the mean glycemia (SD) measured by CGMS for dapagliflozin versus gliclazide MR. 4. Change from baseline to week 12 in glycemic variability measured by the Coefficient of Variation (CV) measured by CGMS for dapagliflozin versus gliclazide MR. 5. Change from baseline to week 12 in the time spent on hypoglycemic range (glycemia \<70mg/dL) measured by CGMS for dapagliflozin versus gliclazide MR. Study design This is a single-center, prospective, randomized, open-label, comparative, phase IV study to compare the effects of gliclazide MR and dapagliflozin on Glycemic Variability in patients with Type 2 Diabetes Mellitus (T2DM). All patients should be treatment naïve or receive standard of care therapy for T2DM as well as for co-morbidities based on accepted guidelines and local best practices. Target patient population Approximately 120 patients with T2DM will be randomized from study site. Patients who were treated with metformin only and had inadequate glycemic control at the time of enrollment as well as treatment naïve or non-medically treated (e.g., diet) patients, will be enrolled and receive either dapagliflozin 10mg qd or comparator gliclazide MR 120mg qd in addition to standard of care treatment for T2DM and co-morbidities. Investigational product, dosage and mode of administration Dapagliflozin 10mg tablets administered orally once daily for 12 weeks. Comparator, dosage and mode of administration Gliclazide MR 60mg tablets administered orally, 2 tablets once daily for 12 weeks. Duration of treatment The treatment with study medication or comparator will have a total duration of 15 weeks.

Key Dates

Start date
Oct 31, 2016
Status verified
Mar 2020
Primary completion
Feb 28, 2018
Completion
Jan 31, 2019

Study Design

Enrollment
135 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin
    The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
  • Active Comparator: Gliclazide MR
    As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.

Primary Outcome Measure

Glycemic Variability [ Time Frame: 12 weeks ]

Related Studies